4DMT Appoints Kristian Humer as Chief Financial Officer - 4D Molecular Therapeutics ( NASDAQ:FDMT )
EMERYVILLE, Calif., Nov. 17, 2025 ( GLOBE NEWSWIRE ) -- 4D Molecular Therapeutics ( NASDAQ:FDMT, 4DMT or the Company ) ) , a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented ...
4DMT Appoints Kristian Humer as Chief Financial Officer
EMERYVILLE, Calif., Nov. 17, 2025 ( GLOBE NEWSWIRE ) -- 4D Molecular Therapeutics ( Nasdaq: FDMT, 4DMT or the Company ) , a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented ...
4DMT Announces New Employment Inducement Grants
EMERYVILLE, Calif., Nov. 14, 2025 ( GLOBE NEWSWIRE ) -- 4D Molecular Therapeutics ( Nasdaq: FDMT, 4DMT or the Company ) , a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented ...
4DMT Announces New Employment Inducement Grants - 4D Molecular Therapeutics ( NASDAQ:FDMT )
EMERYVILLE, Calif., Nov. 14, 2025 ( GLOBE NEWSWIRE ) -- 4D Molecular Therapeutics ( NASDAQ:FDMT, 4DMT or the Company ) ) , a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented ...
4D Molecular Therapeutics, Inc. ( FDMT ) Reports Q3 Loss, Lags Revenue Estimates
4D Molecular Therapeutics (FDMT) delivered earnings and revenue surprises of +0.98% and -91.09%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
4DMT Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants
EMERYVILLE, Calif., Nov. 06, 2025 ( GLOBE NEWSWIRE ) -- 4D Molecular Therapeutics ( Nasdaq: FDMT, 4DMT or the Company ) , a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented ...
4DMT Announces Positive Long-Term Data from Phase 1/2 PRISM Clinical Trial in Wet AMD Supporting 4D-150's Potential as a Backbone Therapy with Consistent and Durable Benefit over Multiple Years
EMERYVILLE, Calif., Nov. 06, 2025 ( GLOBE NEWSWIRE ) -- 4D Molecular Therapeutics ( Nasdaq: FDMT, 4DMT or the Company ) , a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented ...
4DMT Announces Exclusive License Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of 4D-150 in Asia-Pacific
EMERYVILLE, Calif., Oct. 30, 2025 ( GLOBE NEWSWIRE ) -- 4D Molecular Therapeutics ( Nasdaq: FDMT, 4DMT or the Company ) , a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented ...
4DMT Announces New Employment Inducement Grants
EMERYVILLE, Calif., Oct. 17, 2025 ( GLOBE NEWSWIRE ) -- 4D Molecular Therapeutics ( Nasdaq: FDMT, 4DMT or the Company ) , a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented ...
Wall Street Analysts See a 208.52% Upside in 4D Molecular Therapeutics ( FDMT ) : Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 208.5% in 4D Molecular Therapeutics (FDMT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the ...
4DMT to Participate in Chardan's 9th Annual Genetic Medicines Conference
EMERYVILLE, Calif., Oct. 14, 2025 ( GLOBE NEWSWIRE ) -- 4D Molecular Therapeutics ( Nasdaq: FDMT, 4DMT or the Company ) , a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented ...
4DMT Advances 4D-710 to Phase 2 with Additional Funding and Support from the Cystic Fibrosis Foundation - 4D Molecular Therapeutics ( NASDAQ:FDMT )
Cystic Fibrosis Foundation to provide up to $11 million in additional funding to accelerate development of 4D-710 for cystic fibrosis, following program and clinical data review by its independent scientific advisors
4DMT Announces New Employment Inducement Grants
EMERYVILLE, Calif., Sept. 12, 2025 ( GLOBE NEWSWIRE ) -- 4D Molecular Therapeutics ( Nasdaq: FDMT, 4DMT or the Company ) , a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented ...
SNY's Gene Therapy Candidate for Eye Disease Gets FDA Fast Track Tag
Sanofi's gene therapy SAR402663 for wet AMD earns FDA fast track status, aiming to speed up development and reduce treatment burden.
GenVivo Strengthens Oncology Leadership with Appointment of Noriyuki Kasahara, M.D., Ph.D., as Chief Scientific Officer
Scientific Advisory Board member, Dr. Noriyuki Kasahara, appointed Chief Scientific Officer of GenVivo, to accelerate the achievement of major clinical milestones
Jim Cramer: AppLovin Calls For Prudence, This Health Care Stock Is 'Pure Spec' - AppLovin ( NASDAQ:APP ) , Ameris ( NYSE:ABCB )
"Let's take a little off the table just to be prudent," Cramer on AppLovin. SiTime is just a "very good" company, says Cramer. Post-Labor Day Trading Could Trigger Major Market Moves. Here's How to Trade It On CNBC's "Mad Money Lightning Round," Jim Cramer doesn't recommend buying more AppLovin ...
4DMT Announces New Employment Inducement Grants
EMERYVILLE, Calif., Aug. 15, 2025 ( GLOBE NEWSWIRE ) -- 4D Molecular Therapeutics ( Nasdaq: FDMT, 4DMT or the Company ) , a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented ...
4D Molecular Therapeutics, Inc. ( FDMT ) Reports Q2 Loss, Misses Revenue Estimates
4D Molecular Therapeutics (FDMT) delivered earnings and revenue surprises of -11.36% and -98.58%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
4dMT Revenue Jumps 200 Percent in Q2
4d Molecular Therapeutics ( NASDAQ:FDMT ) , a clinical-stage genetic medicines company specializing in targeted gene therapies, reported financial results for the second quarter of fiscal 2025 on August 11, 2025. The headline news was a dramatic revenue surge, with the company delivering $15.0 ...
4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
EMERYVILLE, Calif., Aug. 11, 2025 ( GLOBE NEWSWIRE ) -- 4D Molecular Therapeutics ( Nasdaq: FDMT, 4DMT or the Company ) , a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented ...
4DMT to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference - 4D Molecular Therapeutics ( NASDAQ:FDMT )
EMERYVILLE, Calif., Aug. 06, 2025 ( GLOBE NEWSWIRE ) -- 4D Molecular Therapeutics FDMT 4DMT or the Company ) ) , a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to ...
4D Molecular Therapeutics Rallies On Heels Of Diabetes-Related Vision Study - 4D Molecular Therapeutics ( NASDAQ:FDMT )
4D-150 showed +9.7 letter BCVA gain and 78% fewer injections vs. standard aflibercept in DME. No intraocular inflammation or serious adverse events reported through 60 weeks. Get special access to three exclusive "Top 10 Stocks" power lists today, updated daily.
Why Apple Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - Apple ( NASDAQ:AAPL ) , Bloom Energy ( NYSE:BE )
Shares of Apple Inc. AAPL rose in pre-market trading as the company posted stronger-than-expected third-quarter results. The iPhone maker reported fiscal third-quarter revenue of $94 billion, beating analyst estimates of $89.04 billion by 5.6%.
4DMT Announces Presentations at 43rd Annual Scientific Meeting of the American Society of Retina Specialists
EMERYVILLE, Calif., July 24, 2025 ( GLOBE NEWSWIRE ) -- 4D Molecular Therapeutics ( Nasdaq: FDMT, 4DMT or the Company ) , a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented ...
4DMT Announces Presentations at 43rd Annual Scientific Meeting of the American Society of Retina Specialists - 4D Molecular Therapeutics ( NASDAQ:FDMT )
EMERYVILLE, Calif., July 24, 2025 ( GLOBE NEWSWIRE ) -- 4D Molecular Therapeutics FDMT 4DMT or the Company ) ) , a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to ...
4DMT Announces New Employment Inducement Grants
EMERYVILLE, Calif., July 11, 2025 ( GLOBE NEWSWIRE ) -- 4D Molecular Therapeutics ( Nasdaq: FDMT, 4DMT or the Company ) , a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented ...
4DMT Announces Accelerated 4D-150 Phase 3 Development in Wet AMD and Streamlined Organization to Drive Late-Stage Execution - 4D Molecular Therapeutics ( NASDAQ:FDMT )
4FRONT-1 Phase 3 expected data readout accelerated from H2 2027 to H1 2027 4FRONT-2 Phase 3 trial initiated ahead of schedule Streamlined late-stage clinical and pre-commercial organization aligns with focused pipeline shift, as announced in January 2025
Vivani Medical Appoints Anthony Baldor as Chief Financial Officer - Vivani Medical ( NASDAQ:VANI )
ALAMEDA, Calif., June 11, 2025 ( GLOBE NEWSWIRE ) -- Vivani Medical, Inc. VANI ( "Vivani" or the "Company" ) , a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced the appointment of Anthony Baldor as Chief Financial Officer.
4DMT Announces New Employment Inducement Grants
EMERYVILLE, Calif., May 16, 2025 ( GLOBE NEWSWIRE ) -- 4D Molecular Therapeutics ( Nasdaq: FDMT, 4DMT or the Company ) , a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented ...
4D Molecular Therapeutics, Inc. ( FDMT ) Reports Q1 Loss, Lags Revenue Estimates
4D Molecular Therapeutics (FDMT) delivered earnings and revenue surprises of -2.38% and 98.70%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
4DMT to Participate in Upcoming Investor Conferences
EMERYVILLE, Calif., May 05, 2025 ( GLOBE NEWSWIRE ) -- 4D Molecular Therapeutics ( Nasdaq: FDMT, 4DMT or the Company ) , a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented ...
4DMT to Participate in Upcoming Investor Conferences
EMERYVILLE, Calif., May 05, 2025 ( GLOBE NEWSWIRE ) -- 4D Molecular Therapeutics ( Nasdaq: FDMT, 4DMT or the Company ) , a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented ...
4DMT Announces RMAT Designation Granted by FDA for 4D-150 for DME
4DMT Announces RMAT Designation Granted by FDA for 4D-150 for ...
4DMT Announces RMAT Designation Granted by FDA for 4D-150 for DME
EMERYVILLE, Calif., May 01, 2025 ( GLOBE NEWSWIRE ) -- 4D Molecular Therapeutics ( Nasdaq: FDMT, 4DMT or the Company ) , a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented ...
4DMT Announces New Employment Inducement Grants
EMERYVILLE, Calif., April 11, 2025 ( GLOBE NEWSWIRE ) -- 4D Molecular Therapeutics ( Nasdaq: FDMT, 4DMT or the Company ) , a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented ...
4DMT to Participate in Upcoming Investor Conferences - 4D Molecular Therapeutics ( NASDAQ:FDMT )
EMERYVILLE, Calif., March 27, 2025 ( GLOBE NEWSWIRE ) -- 4D Molecular Therapeutics FDMT 4DMT or the Company ) ) , a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to ...
4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones
EMERYVILLE, Calif., Feb. 28, 2025 ( GLOBE NEWSWIRE ) -- 4D Molecular Therapeutics ( Nasdaq: FDMT, 4DMT or the Company ) , a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented ...
4DMT to Participate in Upcoming Investor Conferences - 4D Molecular Therapeutics ( NASDAQ:FDMT )
EMERYVILLE, Calif., Feb. 19, 2025 ( GLOBE NEWSWIRE ) -- 4D Molecular Therapeutics FDMT 4DMT or the Company ) ) , a leading clinical-stage company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced that management will participate in ...
4DMT to Participate in Upcoming Investor Conferences
EMERYVILLE, Calif., Feb. 19, 2025 ( GLOBE NEWSWIRE ) -- 4D Molecular Therapeutics ( Nasdaq: FDMT, 4DMT or the Company ) , a leading clinical-stage company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced that management will participate ...
Eye Disease Focused 4D Molecular Therapeutics Lays Out 52-Week Results From Wet AMD Study - 4D Molecular Therapeutics ( NASDAQ:FDMT )
4D-150 reduced injection burden by 83% in a subgroup, with 57% remaining injection-free over 52 weeks. BCVA improved by +2.2 letters. In newly diagnosed patients, 87% needed 0-1 injections, and 80% were injection-free. Injection burden dropped by 94% over 52 weeks.
4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program - 4D Molecular Therapeutics ( NASDAQ:FDMT )
3E10 vg/eye achieved an 83% reduction in injection burden vs. projected on-label aflibercept 2 mg Q8W, 70% required 0-1 supplemental injection, and 57% were injection-free through 52 weeks
4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program
EMERYVILLE, Calif., Feb. 08, 2025 ( GLOBE NEWSWIRE ) -- 4D Molecular Therapeutics ( Nasdaq: FDMT. 4DMT or the Company ) , a leading clinical-stage company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced positive initial interim 52-week ...
4DMT Announces Positive Interim Data from 4D-150 SPECTRA Clinical Trial in DME and Alignment with FDA on Registrational Path - 4D Molecular Therapeutics ( NASDAQ:FDMT )
Across all DME patients dosed to date, 4D-150 continues to be well tolerated with no intraocular inflammation observed at any timepoint or dose level 3E10 vg/eye demonstrated strong signals of clinical activity with sustained gain of BCVA of +8.4 letters and reduction of CST of -194 µm from ...
Amazon To Rally Around 21%? Here Are 10 Top Analyst Forecasts For Wednesday - Archer Aviation ( NYSE:ACHR ) , Amazon.com ( NASDAQ:AMZN )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Baird raised the price target for Tesla, Inc. TSLA from $280 to $480.
4D Molecular Therapeutics, Inc. ( FDMT ) Reports Q3 Loss, Lags Revenue Estimates
4D Molecular Therapeutics (FDMT) delivered earnings and revenue surprises of -17.91% and 99.76%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
ARS Pharmaceuticals, Inc. ( SPRY ) Reports Q3 Loss, Misses Revenue Estimates
ARS Pharmaceuticals, Inc. (SPRY) delivered earnings and revenue surprises of -11.11% and 8.50%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Heron Therapeutics ( HRTX ) Reports Q3 Loss, Misses Revenue Estimates
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 0% and 9.86%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Nektar Therapeutics ( NKTR ) Reports Q3 Loss, Tops Revenue Estimates
Nektar (NKTR) delivered earnings and revenue surprises of 21.74% and 55.24%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Ocular Therapeutix ( OCUL ) Moves 6.1% Higher: Will This Strength Last?
Ocular Therapeutix (OCUL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
4D Molecular Therapeutics ( FDMT ) Loses -26.01% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
4D Molecular Therapeutics (FDMT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in ...
